Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy

Roberto Petrioli, Loretta Paolelli, Edoardo Francini, Stefania Marsili, Alessandra Pascucci, Angela Sciandivasci, Giovanni De Rubertis, Gabriele Barbanti, Antonio Manganelli, Francesco Salvestrini, Guido Francini

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of this study was to evaluate the activity and toxicity of capecitabine as third-line treatment in patients with advanced renal cell carcinoma for whom immunotherapy had failed. Twenty-one patients with metastatic clear renal cell carcinoma were enrolled. Capecitabine was administered orally twice daily at a dosage of 2500 mg/m for 14 days, followed by 7 days of rest. The median number of administered cycles was five (1-13). One patient (4.8%) achieved a remission after eight treatment cycles. Stable disease was observed in nine patients (42.8%), whereas 11 progressed (52.4%). The estimated median time to progression was 3.6 months (confidence interval: 1.4 to 5.2). The estimated median overall survival was 7.2 months (confidence interval: 4.6 to 8.8). The regimen was well tolerated and no unexpected toxic effects were observed. Capecitabine as third-line treatment showed a favourable toxicity profile, but exhibited low activity in patients with advanced renal cell carcinoma after failing immunotherapy.

Original languageEnglish
Pages (from-to)817-820
Number of pages4
JournalAnti-Cancer Drugs
Volume18
Issue number7
DOIs
Publication statusPublished - Aug 2007

Keywords

  • Capecitabine
  • Interferon
  • Interleukin-2
  • Renal carcinoma
  • Third-line

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy'. Together they form a unique fingerprint.

Cite this